Exclusive Summary

• Massive Demand & Broad Market: Long-acting G-CSF is a first-line standard prophylactic treatment for Chemotherapy-Induced Neutropenia (CIN). With over 19 million new cancer cases globally per year, this multi-billion dollar supportive care market represents an irreplaceable, rigid demand.
• Differentiated Strength: The unique 2mg/ml in Pre-filled Syringe (PFS) formulation enables distributors to bypass the fierce 'red ocean' competition of the traditional 6mg specification, providing a distinctive competitive advantage in regional bidding and formulary access.
• High Compliance & Convenience: Provided in a ready-to-use PFS to eliminate preparation contamination risk, it requires only a single injection per chemotherapy cycle (replacing daily short-acting G-CSF injections), significantly reducing healthcare burdens and improving patient quality of life.
• Disruptive Cost Advantage: Supported by China's mature biologic manufacturing and PEGylation supply chain, it boasts profound cost advantages over originators (e.g., Neulasta), guaranteeing highly lucrative profit margins and strategic pricing flexibility for overseas distributors.